Colorado drug review board finds J&J's Stelara unaffordable, teeing up potential statewide price cap

Colorado’s Prescription Drug Affordability Review Board (PDAB) isn’t waiting for the Inflation Reduction Act (IRA) to lower prices on certain drugs starting in 2026. After the board previously voted to enforce an upper payment limit on Amgen’s Enbrel in the state, Johnson & Johnson’s Stelara could be next in line.